Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.444
+0.006 (1.32%)
At close: Apr 28, 2026, 4:00 PM EDT
0.435
-0.009 (-1.98%)
Pre-market: Apr 29, 2026, 9:00 AM EDT
Silo Pharma Revenue
In the year 2025, Silo Pharma had annual revenue of $72.10K. Silo Pharma had revenue of $18.03K in the quarter ending December 31, 2025.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
100.12
Revenue / Employee
$24,034
Employees
3
Market Cap
7.22M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 4.99M |
| Xenetic Biosciences | 2.98M |
| BioAtla | 2.00M |
| Addex Therapeutics | 198.82K |
| Creative Medical Technology Holdings | 6.00K |
SILO News
- 6 days ago - Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents - GlobeNewsWire
- 21 days ago - Silo Pharma Rallies After Securing Key Patent Allowance - Benzinga
- 22 days ago - Stock Market Today: Dow, S&P 500 Futures Rise Ahead Of Trump's 'Power Plant Day' Deadline—UnitedHealth, Silo Pharma, Phillips 66 In Focus - Benzinga
- 22 days ago - Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy - GlobeNewsWire
- 2 months ago - Silo Pharma Announces Share Buyback Program - GlobeNewsWire
- 2 months ago - Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio - GlobeNewsWire
- 4 months ago - Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 - GlobeNewsWire
- 5 months ago - Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD - GlobeNewsWire